TY - JOUR

T1 - CVOT Summit Report 2023

T2 - new cardiovascular, kidney, and metabolic outcomes

AU - Schnell, Oliver

AU - Barnard-Kelly, Katharine

AU - Battelino, Tadej

AU - Ceriello, Antonio

AU - Larsson, Helena Elding

AU - Fernández-Fernández, Beatriz

AU - Forst, Thomas

AU - Frias, Juan Pablo

AU - Gavin, James R.

AU - Giorgino, Francesco

AU - Groop, Per Henrik

AU - Heerspink, Hiddo J.L.

AU - Herzig, Stephan

AU - Hummel, Michael

AU - Huntley, George

AU - Ibrahim, Mahmoud

AU - Itzhak, Baruch

AU - Jacob, Stephan

AU - Ji, Linong

AU - Kosiborod, Mikhail

AU - Lalic, Nebosja

AU - Macieira, Sofia

AU - Malik, Rayaz A.

AU - Mankovsky, Boris

AU - Marx, Nikolaus

AU - Mathieu, Chantal

AU - Müller, Timo D.

AU - Ray, Kausik

AU - Rodbard, Helena W.

AU - Rossing, Peter

AU - Rydén, Lars

AU - Schumm-Draeger, Petra Maria

AU - Schwarz, Peter

AU - Škrha, Jan

AU - Snoek, Frank

AU - Tacke, Frank

AU - Taylor, Bruce

AU - Jeppesen, Britta Tendal

AU - Tesfaye, Solomon

AU - Topsever, Pinar

AU - Vilsbøll, Tina

AU - Yu, Xuefeng

AU - Standl, Eberhard

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024

Y1 - 2024

N2 - The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).

AB - The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 (http://www.cvot.org).

KW - Cardiovascular disease

KW - CGM

KW - Chronic kidney disease

KW - Diabetes

KW - Finerenone

KW - GLP-1 RA

KW - Guidelines

KW - Heart failure

KW - MASLD

KW - NAFLD

KW - Obesity

KW - SGLT2 inhibitor

KW - Teplizumab

U2 - 10.1186/s12933-024-02180-8

DO - 10.1186/s12933-024-02180-8

M3 - Comment/debate

C2 - 38504284

AN - SCOPUS:85188142815

VL - 23

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 104

ER -